Hodgkin Lymphoma : A Comprehensive Overview /
This book examines in detail the current treatment options for first-line, relapsed, and refractory Hodgkin lymphoma and the management appropriate in special clinical circumstances, including in the elderly, pregnant women, and those with lymphocyte-predominant disease. Careful attention is devoted...
Saved in:
Corporate Author: | |
---|---|
Other Authors: | , |
Format: | eBook |
Language: | English |
Published: |
Cham :
Springer International Publishing : Imprint: Springer,
2015.
|
Edition: | 2nd ed. 2015. |
Series: | Hematologic Malignancies,
|
Subjects: | |
Online Access: | Click here to view the full text content |
Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Table of Contents:
- Part I: From Hodgkin's disease to Hodgkin Lymphoma: Epidemiology
- The role of viruses in the genesis of Hodgkin Lymphoma
- Pathology and molecular pathology of Hodgkin Lymphoma
- Microenvironment, cross-talk and immune escape mechanisms
- What will we learn from Genomics and Proteomics in Hodgkin Lymphoma? Part II: Diagnosis and treatment:Clinical evaluation
- Functional imaging
- Prognostic factors
- Principles of radiation techniques in Hodgkin Lymphoma
- Principles of chemotherapy in Hodgkin Lymphoma
- Treatment of early favorable Hodgkin Lymphoma
- Treatment of early unfavorable Hodgkin Lymphoma
- Treatment of advanced-stage Hodgkin Lymphoma
- Relapsed and refractory Hodgkin Lymphoma
- Paediatric Hodgkin Lymphoma. Part III: Special Clinical Situations: Lymphocyte-predominant Hodgkin Lymphoma
- The management of Hodgkin Lymphoma during pregnancy
- The management of HIV-Hodgkin Lymphoma
- The management of elderly patients with Hodgkin Lymphoma
- Allogeneic transplantation for relapsed of Hodgkin Lymphoma
- Targeting CD 30
- Other new agents for patients with Hodgkin Lymphoma. Part IV: Survivorship: Quality of Life in Hodgkin Lymphoma
- Second malignancy risk after treatment of Hodgkin Lymphoma
- Cardiovascular and pulmonary late effects
- Gonadal dysfunction and fertility preservation in Hodgkin Lymphoma patients.